Novartis gets Breakthrough designation for its CAR-T therapy; Duchesney continues working with Kardashian; new user-fee deal to speed up FDA approvals
A study published in Health Affairs detailed an outcomes-based pilot developed by the drugmaker and Priority Health, a Michigan-based health insurer.
Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose
Diane Jooris is co-founder and CEO of OnComfort.
Dr. Christiana Bardon is managing director of the Oncology Impact Fund for MPM Capital.
Renee Rodgers is executive director and head of digital strategy for U.S. oncology at Novartis.
Brandi Davis-Dusenbery is CEO of Seven Bridges.
Opdivo/Yervoy combination shows improved survival for melanoma patients in trial; global immunotherapy market likely to reach $75 billion by 2022; Mylan expands EpiPen recall
Novartis CAR-T drug receives priority review; addiction center's ad compares addiction to cancer; Arizona passes off-label law
Ovarian cancer drug nabs FDA approval; Senate committee to investigate opioid manufacturers; Allergan's acne drug reports positive Phase-III results
A high-profile cancer track commands attention, while wearables and IBM Watson Health come under fire.
Novartis' Gleevec shows long-term survival benefit in study; Novo Nordisk CEO considers small acquisitions; Merck KGaA to sell biosimilars unit
Harvard Pilgrim signs pay-for-performance deals with Lilly and Amgen; new advocacy group wants lower drug prices; Zykadia gets priority review
Few questions give healthcare marketers more heart palpitations than this one: "How do you know it will work?"
Ads promoting Merck's and Bristol-Myers Squibb's immunotherapies could signal the beginning of a new era for DTC.
Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer
The 2009 documentary offers a wealth of detail. Which is why it makes no sense that Genentech doesn't want you to see the damn thing.
Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.
Rep. Price to answer questions at confirmation hearing; 22 drugmakers invest in fighting disease in poor countries; FDA approves generic of Jazz's Xyrem
"In Australia, we are the healthcare industry," he says.
Trump says pharma is "getting away with murder"; Senate majority votes to repeal ACA; IBM Watson Health and FDA to study blockchain technology
Illumina and IBM enter DNA sequencing partnership; J&J to outline price increases in new report; Egalet's opioid Arymo ER gets FDA approval
Sanofi, Regeneron denied bid to overturn Amgen win in patent case; Abbott to close St. Jude deal; Gilead hires SVP of hematology and oncology
Drugmakers promote new type of opioid with unproven results; Heritage execs charged for price-fixing generics; Pershing sells more Valeant shares
The FDA approves new indication for Jardiance; Novartis' CAR-T therapy eliminates leukemia in 82% of patients in trial; doctors report risks associated with immunotherapy
Regeneron and Pfizer CEOs argue about the industry's reputation; Mylan CEO defends the EpiPen; Pfizer and IBM to partner on cancer immunotherapies
How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy
Intarcia submits diabetes drug-delivery pump for FDA approval; Shire to build rare-disease innovation hub; AstraZeneca to resume durvalumab trials
"This is not your grandfather's launch," said Shawn Tomasello, chief commercial officer of Kite Pharma.
Novartis' Entresto and Cosentyx miss sales forecasts; faith-based investor group urges pricing transparency; Amgen invests in digital health
- Five things for pharma marketers to know: Monday, April 24, 2017
- Five things for pharma marketers to know: Thursday, April 20, 2017
- Five things for pharma marketers to know: Friday, April 21, 2017
- Five things for pharma marketers to know: Tuesday, April 25, 2017
- Five things for pharma marketers to know: Wednesday, April 26, 2017
- How pharma marketers are using behavioral science
- Veeva and QuintilesIMS tussle over customer reference data
- Genentech urges broader adoption of value-based payment models
- Some brands thought to shift online ad dollars, creating uncertainty for WebMD
- Study: Medical-marijuana laws lower prescription drug usage